Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.
University of Zurich, Zurich, Switzerland.
Retina. 2018 Sep;38(9):1824-1829. doi: 10.1097/IAE.0000000000001788.
Evaluation of the influence of long-term intravitreal anti-vascular endothelial growth factor treatment on preexisting retinal microstructural alterations in patients with diabetic macular edema.
Eyes with diabetic macular edema and a history of ≥ 20 intravitreal anti-vascular endothelial growth factor (aflibercept and/or ranibizumab) injections were included in this retrospective study. Primary outcome was the extent of disorganization of retinal inner layers, alterations at the outer plexiform layer/Henle fiber layer junction, disruption of external limiting membrane/ellipsoid zone, disruption of retinal pigment epithelium/Bruch complex, and retinal atrophy at baseline versus after ≥ 20 intravitreal injections as visualized by spectral-domain optical coherence tomography images.
Of 383 eyes screened, 37 eyes were included in the current study. With the exception of outer plexiform layer/Henle fiber layer junction restoration, no significant changes regarding microstructural alterations between baseline and end of study were encountered after long-term anti-vascular endothelial growth factor (disorganization of retinal inner layers P = 0.381, outer plexiform layer/Henle fiber layer junction P = 0.001, external limiting membrane/ellipsoid zone P = 0.524, retinal pigment epithelium/Bruch complex P = 0.122, retinal atrophy P = 0.317). Best-corrected visual acuity significantly increased over the course of the study, corresponding to central retinal thickness and intraretinal fluid reduction (all P < 0.0001). The extent of microstructural alterations was negatively correlated with best-corrected visual acuity (P < 0.05).
Apart from outer plexiform layer/Henle fiber layer junction layer restoration, no effect on preexisting retinal alterations was encountered after long-term intravitreal injections. Thus, intravitreal ranibizumab or aflibercept did not have a major effect (neither positive nor negative) on microstructural alterations.
评估长期玻璃体内抗血管内皮生长因子治疗对糖尿病黄斑水肿患者原有视网膜微观结构改变的影响。
本回顾性研究纳入了有糖尿病黄斑水肿病史且接受过≥20 次玻璃体内抗血管内皮生长因子(阿柏西普和/或雷珠单抗)治疗的患者。主要结局是评估基线时与≥20 次玻璃体内注射后视网膜内层紊乱、外丛状层/Henle 纤维层交界处改变、外界膜/椭圆体带中断、视网膜色素上皮/脉络膜复合体中断和视网膜萎缩的程度,通过频域光学相干断层扫描图像进行评估。
在筛选的 383 只眼中,有 37 只眼纳入本研究。除了外丛状层/ Henle 纤维层交界处恢复外,长期抗血管内皮生长因子治疗后,微观结构改变与基线相比没有显著变化(视网膜内层紊乱 P = 0.381,外丛状层/ Henle 纤维层交界处 P = 0.001,外界膜/椭圆体带 P = 0.524,视网膜色素上皮/脉络膜复合体 P = 0.122,视网膜萎缩 P = 0.317)。最佳矫正视力在研究过程中显著增加,与中心视网膜厚度和视网膜内液减少相对应(均 P < 0.0001)。微观结构改变的程度与最佳矫正视力呈负相关(P < 0.05)。
除了外丛状层/ Henle 纤维层交界处恢复外,长期玻璃体内注射对原有视网膜改变没有影响。因此,玻璃体内雷珠单抗或阿柏西普对微观结构改变没有明显作用(既没有积极作用,也没有消极作用)。